Netenax (Netilmicin)

Netilmicin, the active ingredient in Netenax, binds to the bacterial 30S ribosomal subunit, disrupting protein synthesis. This causes misreading of messenger RNA, leading to the production of faulty proteins and ultimately bacterial cell death, providing a rapid bactericidal effect against susceptible ocular pathogens.

The dosing regimen for Netenax is determined by the prescribing clinician based on the specific infection, severity and patient factors. The prescriber will specify the number of drops, frequency and duration of treatment appropriate for the diagnosed ocular condition.

Safety data for netilmicin in pregnancy and lactation are limited. Use during pregnancy or while breastfeeding should only occur if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To order Netenax, submit an enquiry on the product page at gnhindia.com, indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Netenax (netilmicin) belongs to the aminoglycoside class, offering broad‑spectrum activity against Gram‑negative and some Gram‑positive bacteria. Compared with fluoroquinolone eye drops, it may have a lower risk of resistance development but requires careful monitoring for renal or ototoxic effects, especially with prolonged use.

Netenax should be stored at room temperature, away from direct sunlight and moisture. Keep the vial in its original packaging, ensure the cap is tightly closed, and discard any solution that appears discolored or contaminated.

Netenax is applied as eye drops. The prescribed number of drops is placed into the conjunctival sac of the affected eye(s) at the frequency indicated by the prescriber, usually avoiding contact with the eyelid or eyelashes to maintain sterility.

Serious risks include allergic reactions such as contact dermatitis, corneal ulceration, and, rarely, systemic nephrotoxicity or ototoxicity if significant systemic absorption occurs. Patients should be instructed to seek immediate medical attention if severe eye pain, vision changes or systemic symptoms develop.

Netenax should not be used by individuals with a known hypersensitivity to netilmicin or any other aminoglycoside. It is also contraindicated in viral, fungal or non‑infectious inflammatory eye conditions where an antibacterial agent would be ineffective.